Square Pharmaceuticals PLC. (DSE:SQURPHARMA)

DSE:SQURPHARMA Balance Sheet

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	58,326	55,396	52,013	50,094	48,962	43,364
Cash & Short-Term Investments	58,326	55,396	52,013	50,094	48,962	43,364
Cash Growth	5.49%	6.50%	3.83%	2.31%	12.91%	33.16%
Accounts Receivable	5,105	2,236	2,551	3,421	2,159	1,636
Other Receivables	-	1,875	1,952	2,702	1,236	1,280
Receivables	5,105	4,111	4,503	6,122	3,395	2,916
Inventory	13,506	13,059	12,582	12,227	8,214	7,245
Prepaid Expenses	-	113.44	101.51	81.62	57.56	46.17
Other Current Assets	1,955	1,882	2,005	1,962	1,718	1,505
Total Current Assets	78,893	74,562	71,206	70,487	62,348	55,076
Property, Plant & Equipment	32,327	31,687	27,750	26,059	27,183	22,884
Long-Term Investments	45,584	40,566	33,682	25,270	22,227	17,492
Other Intangible Assets	-	0.03	0.05	0.11	-	-
Total Assets	156,803	146,815	132,637	121,816	111,758	95,452
Accounts Payable	1,491	1,375	1,455	1,002	625.98	666.17
Accrued Expenses	295.7	1,552	1,476	1,327	1,257	1,121
Current Portion of Long-Term Debt	568.5	625.5	614.54	618.61	200	-
Current Income Taxes Payable	1,738	1,307	912.27	356.1	911.5	572.68
Other Current Liabilities	2,949	964.58	823.65	926.1	666.85	818.87
Total Current Liabilities	7,042	5,823	5,282	4,229	3,662	3,179
Long-Term Debt	100	200	814.54	1,368	1,714	103.71
Long-Term Deferred Tax Liabilities	1,177	836.12	619.08	1,022	1,179	1,275
Total Liabilities	8,319	6,860	6,716	6,620	6,555	4,557
Common Stock	8,865	8,865	8,865	8,865	8,865	8,865
Additional Paid-In Capital	2,035	2,035	2,035	2,035	2,035	2,035
Retained Earnings	137,578	129,050	115,019	103,578	93,463	78,855
Comprehensive Income & Other	-	-	-	717.6	839.61	1,139
Total Common Equity	148,478	139,950	125,919	115,196	105,203	90,895
Minority Interest	6.5	5.44	2.32	0.71	0.47	0.5
Shareholders' Equity	148,485	139,956	125,922	115,197	105,203	90,895
Total Liabilities & Equity	156,803	146,815	132,637	121,816	111,758	95,452
Total Debt	668.5	825.5	1,429	1,987	1,914	103.71
Net Cash (Debt)	69,474	64,616	59,877	52,697	51,395	47,885
Net Cash Growth	8.40%	7.92%	13.62%	2.53%	7.33%	35.82%
Net Cash Per Share	78.37	72.89	67.55	59.45	57.98	54.02
Filing Date Shares Outstanding	886.65	886.45	886.45	886.45	886.45	886.45
Total Common Shares Outstanding	886.65	886.45	886.45	886.45	886.45	886.45
Working Capital	71,851	68,738	65,924	66,258	58,686	51,898
Book Value Per Share	167.46	157.88	142.05	129.95	118.68	102.54
Tangible Book Value	148,478	139,950	125,919	115,196	105,203	90,895
Tangible Book Value Per Share	167.46	157.88	142.05	129.95	118.68	102.54
Land	-	8,851	8,486	6,632	6,446	6,136
Buildings	-	12,115	11,897	11,716	10,317	9,756
Machinery	-	34,177	30,559	29,322	26,788	25,510
Construction In Progress	-	2,983	1,318	1,083	6,388	2,460

Source: S&P Global Market Intelligence. Standard template. Financial Sources.